Cytiva and NecstGen team up to accelerate development of cell and gene therapies
The partnership will focus on bringing research into clinical trials. Life science company Cytiva will provide its technologies, services, and solutions to NecstGen, a non-profit CDMO founded in 2020 as a center of excellence for cell and gene therapy in the Netherlands. Both organizations will share their knowledge, expertise, and learnings.
Catarina Flyborg, vice president, Cell and Gene Therapy, Cytiva says: “Cell and gene therapies are transformative medicines and accelerating their development requires harnessing the power of the industry. By sharing our expertise and providing NecstGen with access to our team of specialists, Cytiva will play a critical role in taking translational research from the laboratory to the bedside.”
NecstGen brings the development, production, QC, QA, and QP functions together in a new 4,000 m2 facility in Leiden Bio Science Park, the largest bio-cluster in the Netherlands. The facility will serve all organizations worldwide, but with a particular focus on academic and small/large industry enterprises who want to bring their research to the clinical stage. NecstGen will provide process development, cGMP manufacturing services up to 200L, and cleanroom rental.
Paul Bilars, CEO, NecstGen, says: “Our partnership with Cytiva will provide us with the flexible and scalable solutions needed by pioneers in the field of cell and gene therapy. Working together, we will accelerate the development of future therapies, bringing these to patients faster.”
During the first half of 2021, there were 1,328 regenerative medicine trials underway globally sponsored by non-industry groups such as academic centers and government entities, according to figures from the Alliance for Regenerative Medicine.